ATRA
Atara Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.69
−0.21%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$9.91
From 52W high−46.43%
Volume37766.00
Market cap$97.27M
P/E (TTM)—
P/S (TTM)15.7x
Div yield—
Key dataSep 18, 2026
Open
$9.91
From 52W high
−46.43%
Volume
37766.00
Market cap
$97.27M
ValuationView details →
P/E (Fwd)
15.0x
EV/EBITDA
−7.1x
P/E (TTM)
—
RSI (14)
54.0
MomentumView details →
1D Return
−0.21%
YTD Return
−46.21%
SummaryUpdated Jun 1, 2026
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a clinical-stage biotechnology company founded in 2012 and headquartered in South San Francisco, California. The company went public in October 2014 and specializes in developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. Atara has evolved from a broad-based immunotherapy developer to a more focused organization following strategic partnerships and operational restructuring in recent years.
Similar companies
Latest newsMore news →